Given that the Policy Position: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis was due to be reviewed in August 2017, when does the Cabinet Secretary expect the Welsh Health Specialised Services Committee to complete its review so that it has an up-to-date policy on which to base decisions about treating patients from Wales?
August 2017 was the earliest commencement date for the Welsh Health Specialised Services Committee (WHSSC) to review their commissioning policy for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis.
CRS and HIPEC is already a treatment option for pseudomyxoma peritonei and available under extant WHSSC policy.
WHSSC intend to produce an overarching CRS and HIPEC policy for all peritoneal malignancies and have commissioned the Cedar Health Technology Research Centre to review the evidence on the clinical and cost effectiveness of CRS and HIPEC for both peritoneal carcinomatosis and pseudomyxoma peritonei.
The review is expected to complete in May 2018.